What does common stock shares outstanding mean?

This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.

Citius Oncology, Inc. CTOR Common Stock Shares Outstanding

Common Stock Shares Outstanding at other companies

Merck & Co.MRK

$275M+10.4%

Delcath SystemsDCTH

$13.93M-56.3%

ImmunityBio, Inc.IBRX

——

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-75.9%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s common stock shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s common stock shares outstanding?: Citius Oncology, Inc. (CTOR) reported common stock shares outstanding of $5.39M in Q3 2026.
What does common stock shares outstanding mean?: This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.